Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Hands-on biotech training delivers credentials, research projects, and real lab access for San Antonio students—fueling ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full ...

Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Picture a world where most life-saving medicines are discovered not in the United States, but in Beijing and Shanghai. Imagine a time when the most advanced biotechnologies, therapies that cure cancer ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The EU is planning to boost biotechnology. A recent report laying out its commitment to the sector won a vote in the European Parliament last week. While the report covered biotechnology as a whole, ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...